US Stock MarketDetailed Quotes
QURE uniQure NV
- 5.788
- +0.248+4.47%
Trading Sep 13 13:57 ET
281.84MMarket Cap-977P/E (TTM)
5.790High5.520Low142.88KVolume5.570Open5.540Pre Close810.52KTurnover0.38%Turnover RatioLossP/E (Static)48.70MShares11.35052wk High2.90P/B219.84MFloat Cap3.73052wk Low--Dividend TTM37.99MShs Float82.490Historical High--Div YieldTTM4.87%Amplitude3.730Historical Low5.672Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
uniQure NV Stock Forum
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
uniQure N.V. (NASDAQ: QURE) has initiated dosing in a Phase I/IIa clinical trial of AMT-191 for Fabry diseasetreatment. The multi-center, open-label trial in the US will assess safety, tolerability, and early efficacy signs in two dose-escalating cohorts. AMT-191 is an AAV5-based gene therapy delivering a galactosidase alpha (GLA) transgene to the live...
No comment yet